miR‑101 regulates the cell proliferation and apoptosis in diffuse large B‑cell lymphoma by targeting MEK1 via regulation of the ERK/MAPK signaling pathway

Huang,Yiqun; Zou,Yong; Lin,Luhui; Ma,Xudong; Zheng,Ruiji

doi:10.3892/or.2018.6821

miR‑101 regulates the cell proliferation and apoptosis in diffuse large B‑cell lymphoma by targeting MEK1 via regulation of the ERK/MAPK signaling pathway

Authors:
- Yiqun Huang
- Yong Zou
- Luhui Lin
- Xudong Ma
- Ruiji Zheng
View Affiliations

Affiliations: Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, P.R. China
Published online on: October 24, 2018 https://doi.org/10.3892/or.2018.6821
Pages: 377-386

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MAPK kinase 1 (MEK1) is an upstream protein kinase of extracellular signal regulated kinase (ERK), which activates the ERK/MAPK (mitogen activated protein kinase) pathway. Importantly, bioinformatic analysis has shown that there is a target complementary binding site between miR‑101 and MEK1. The present study aimed to ascertain whether or not miR‑101 plays a role in regulating MEK1 expression, ERK/MAPK pathway activity, and the proliferation and apoptosis in a diffuse large B cell lymphoma (DLBCL) cell line. DLBCL tumor samples were collected from patients in our hospital, and lymphatic tissues with reactive lymphoid hyperplasia were selected as controls. The patients were divided into high and low expression groups, and then the survival rate of the two groups was compared using Kaplan‑Meier method, as well the effect of miR‑101 and MEK1 mRNA expression on survival and prognosis was analyzed. The expression of miR‑101, MEK1 and p‑MEK1 between normal lymphoblastic cell lines (HCC1954 BL and NCI‑BL2009) and lymphoma cell lines (SU‑DHL‑4 and Farage) was compared. Lymphoma SU‑DHL‑4 and Farage cells were cultured in vitro, and then divided into the following groups: miR‑NC group; miR‑101 mimic group; siRNA‑NC group; and siRNA‑MEK1 group. The expression of miR‑101, MEK1, p‑MEK1, p‑ERK1/2 and Bcl‑2 was compared. Cell apoptosis was detected by flow cytometry, and cell proliferation was detected by EdU staining. The results showed that targeted regulation existed between miR‑101 and MEK1, and the decreased expression of miR‑101 was related to the pathogenesis and prognosis of DLBCL. Upregulation of miR‑101 inhibited DLBCL cell proliferation and facilitated apoptosis by inhibiting the expression of MEK1.

View Figures

View References

1	Luminari S: Bridging the gap between epidemiology and clinical research in lymphoma. Leuk Lymphoma. 54:1855–1856. 2013. View Article : Google Scholar : PubMed/NCBI
2	Smedby KE and Hjalgrim H: Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 21:293–298. 2011. View Article : Google Scholar : PubMed/NCBI
3	Skrabek P, Turner D and Seftel M: Epidemiology of non-Hodgkin lymphoma. Transfus Apher Sci. 49:133–138. 2013. View Article : Google Scholar : PubMed/NCBI
4	Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR and Skettino S: Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: A surveillance, epidemiology, and end results-medicare analysis. Oncologist. 19:1249–1257. 2014. View Article : Google Scholar : PubMed/NCBI
5	Castillo JJ, Winer ES and Olszewski AJ: Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the surveillance, epidemiology and end results database. Am J Hematol. 89:310–314. 2014. View Article : Google Scholar : PubMed/NCBI
6	Gysin S, Paquette J and McMahon M: Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity. Mol Cancer Res. 10:1607–1619. 2012. View Article : Google Scholar : PubMed/NCBI
7	Pénzváltó Z, Lánczky A, Lénárt J, Meggyesházi N, Krenács T, Szoboszlai N, Denkert C, Pete I and Győrffy B: MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. BMC Cancer. 14:8372014. View Article : Google Scholar : PubMed/NCBI
8	Song JY, Kim CS, Lee JH, Jang SJ, Lee SW, Hwang JJ, Lim C, Lee G, Seo J, Cho SY and Choi J: Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation. Invest New Drugs. 31:1458–1465. 2013. View Article : Google Scholar : PubMed/NCBI
9	Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P and Grant S: Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leuk Res. 34:379–386. 2010. View Article : Google Scholar : PubMed/NCBI
10	Zheng W, Liu Z, Zhang W and Hu X: miR-31 functions as an oncogene in cervical cancer. Arch Gynecol Obstet. 292:1083–1089. 2005. View Article : Google Scholar
11	Wang LQ, Zhang Y, Yan H, Liu KJ and Zhang S: MicroRNA-373 functions as an oncogene and targets YOD1 gene in cervical cancer. Biochem Biophys Res Commun. 459:515–520. 2015. View Article : Google Scholar : PubMed/NCBI
12	Mou Z, Xu X, Dong M and Xu J: MicroRNA-148b acts as a tumor suppressor in cervical cancer by inducing G1/S-phase cell cycle arrest and apoptosis in a caspase-3-dependent manner. Med Sci Monit. 22:2809–2815. 2016. View Article : Google Scholar : PubMed/NCBI
13	Fan D, Wang Y, Qi P, Chen Y, Xu P, Yang X, Jin X and Tian X: MicroRNA-183 functions as the tumor suppressor via inhibiting cellular invasion and metastasis by targeting MMP-9 in cervical cancer. Gynecol Oncol. 141:166–174. 2016. View Article : Google Scholar : PubMed/NCBI
14	Chen LG, Xia YJ and Cui Y: Upregulation of miR-101 enhances the cytotoxic effect of anticancer drugs through inhibition of colon cancer cell proliferation. Oncol Rep. 38:100–108. 2017. View Article : Google Scholar : PubMed/NCBI
15	Lin C, Huang F, Li QZ and Zhang YJ: miR-101 suppresses tumor proliferation and migration, and induces apoptosis by targeting EZH2 in esophageal cancer cells. Int J Clin Exp Pathol. 7:6543–6550. 2014.PubMed/NCBI
16	Liu L, Guo J, Yu L, Cai J, Gui T, Tang H, Song L, Wang J, Han F, Yang C, et al: miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. Tumour Biol. 35:12619–12626. 2014. View Article : Google Scholar : PubMed/NCBI
17	Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, Weisenburger DD, et al: MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood. 118:5550–5558. 2011. View Article : Google Scholar : PubMed/NCBI
18	Ng SB, Yan J, Huang G, Selvarajan V, Tay JL, Lin B, Bi C, Tan J, Kwong YL, Shimizu N, et al: Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood. 118:4919–4929. 2011. View Article : Google Scholar : PubMed/NCBI
19	Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL and Flowers CR: New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev Anticancer Ther. 15:531–544. 2015. View Article : Google Scholar : PubMed/NCBI
20	Pancione M, Giordano G, Parcesepe P, Cerulo L, Coppola L, Curatolo AD, Conciatori F, Milella M and Porras A: Emerging insight into MAPK inhibitors and immunotherapy in colorectal cancer. Curr Med Chem. 24:1383–1402. 2017. View Article : Google Scholar : PubMed/NCBI
21	Zhang X, Liu K, Zhang T, Wang Z, Qin X, Jing X, Wu H, Ji X, He Y and Zhao R: Cortactin promotes colorectal cancer cell proliferation by activating the EGFR-MAPK pathway. Oncotarget. 8:1541–1554. 2017.PubMed/NCBI
22	Buchegger K, Silva R, López J, Ili C, Araya JC, Leal P, Brebi P, Riquelme I and Roa JC: The ERK/MAPK pathway is overexpressed and activated in gallbladder cancer. Pathol Res Pract. 213:476–482. 2017. View Article : Google Scholar : PubMed/NCBI
23	Liao T, Wen D, Ma B, Hu JQ, Qu N, Shi RL, Liu L, Guan Q, Li DS and Ji QH: Yes-associated protein 1 promotes papillary thyroid cancer cell proliferation by activating the ERK/MAPK signaling pathway. Oncotarget. 8:11719–11728. 2017. View Article : Google Scholar : PubMed/NCBI
24	Zheng ST, Huo Q, Tuerxun A, Ma WJ, Lv GD, Huang CG, Liu Q, Wang X, Lin RY, Sheyhidin I and Lu XM: The expression and activation of ERK/MAPK pathway in human esophageal cancer cell line EC9706. Mol Biol Rep. 38:865–872. 2011. View Article : Google Scholar : PubMed/NCBI
25	Chen P, Xu W, Luo Y, Zhang Y, He Y, Yang S and Yuan Z: MicroRNA 543 suppresses breast cancer cell proliferation, blocks cell cycle and induces cell apoptosis via direct targeting of ERK/MAPK. Onco Targets Ther. 10:1423–1431. 2017. View Article : Google Scholar : PubMed/NCBI
26	Koyama T, Ogawara K, Kasamatsu A, Okamoto A, Kasama H, Minakawa Y, Shimada K, Yokoe H, Shiiba M, Tanzawa H, et al: ANGPTL3 is a novel biomarker as it activates ERK/MAPK pathway in oral cancer. Cancer Med. 4:759–769. 2015. View Article : Google Scholar : PubMed/NCBI
27	Lu Z, Ding L, Hong H, Hoggard J, Lu Q and Chen YH: Claudin-7 inhibits human lung cancer cell migration and invasion through ERK/MAPK signaling pathway. Exp Cell Res. 317:1935–1946. 2011. View Article : Google Scholar : PubMed/NCBI
28	Wong KK: Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov. 4:28–35. 2009. View Article : Google Scholar : PubMed/NCBI
29	Sasaki D, Imaizumi Y, Hasegawa H, Osaka A, Tsukasaki K, Choi YL, Mano H, Marquez VE, Hayashi T, Yanagihara K, et al: Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica. 96:712–719. 2011. View Article : Google Scholar : PubMed/NCBI
30	Ferreira AC, Robaina MC, Rezende LM, Severino P and Klumb CE: Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101. Ann Hematol. 93:983–993. 2014.PubMed/NCBI
31	Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, Egger G, Hassler MR, Thallinger C, Schmatz A, et al: Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)⁺ and ALK⁻ anaplastic large-cell lymphoma. Proc Natl Acad Sci USA. 107:16228–16233. 2010. View Article : Google Scholar : PubMed/NCBI
32	Qian L, Zhang W, Lei B, He A, Ye L, Li X and Dong X: MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting Notch1. Oncol Rep. 36:2511–2516. 2016. View Article : Google Scholar : PubMed/NCBI
33	Liu X, Zou L, Zhu L, Zhang H, Du C, Li Z, Gao C, Zhao X, Bao S and Zheng H: miRNA mediated up-regulation of cochaperone p23 acts as an anti-apoptotic factor in childhood acute lymphoblastic leukemia. Leuk Res. 36:1098–1104. 2012. View Article : Google Scholar : PubMed/NCBI
34	Gahl RF, Dwivedi P and Tjandra N: Bcl-2 proteins bid and bax form a network to permeabilize the mitochondria at the onset of apoptosis. Cell Death Dis. 7:e24242016. View Article : Google Scholar : PubMed/NCBI
35	Jagani H, Kasinathan N, Meka SR and Josyula VR: Antiapoptotic Bcl-2 protein as a potential target for cancer therapy: A mini review. Artif Cells Nanomed Biotechnol. 44:1212–1221. 2016.PubMed/NCBI
36	Um HD: Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget. 7:5193–5203. 2016. View Article : Google Scholar : PubMed/NCBI
37	Sivakumar D and Sivaraman T: A review on structures and functions of Bcl-2 family proteins from homo sapiens. Protein Pept Lett. 23:932–941. 2016. View Article : Google Scholar : PubMed/NCBI
38	Yang D, Chen MB, Wang LQ, Yang L, Liu CY and Lu PH: Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: A systematic review and meta-analysis. J Exp Clin Cancer Res. 32:1052013. View Article : Google Scholar : PubMed/NCBI
39	Kumar SR, Kim DY, Henry CJ, Bryan JN, Robinson KL and Eaton AM: Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors. Vet Comp Oncol. 15:1527–1536. 2017. View Article : Google Scholar : PubMed/NCBI